<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783549</url>
  </required_header>
  <id_info>
    <org_study_id>111596</org_study_id>
    <nct_id>NCT00783549</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.</brief_title>
  <official_title>A Study in Healthy Volunteers of Single Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first study in humans to assess the safety and tolerability of various
      doses of GSK1292263 alone, and taken with sitigliptan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2008</start_date>
  <completion_date type="Actual">March 31, 2009</completion_date>
  <primary_completion_date type="Actual">March 31, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability parameters including adverse events, clinical laboratory, electrocardiogram, and vital signs assessments.</measure>
    <time_frame>Up to 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters, maximum observed plasma drug concentration, time to maximum observe.</measure>
    <time_frame>Up to 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints</measure>
    <time_frame>Up to four days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢ Pharmacokinetic parameters following a dose, with and without food, and bioavailability</measure>
    <time_frame>Up to four days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships betwen drug exposures and pharmacodynamic parameters, safety, and tolerability, as appropriate.</measure>
    <time_frame>Up to four days.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Dyslipidaemias</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 active 2 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 active 3 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>an undetermined dose of GSK1292263</intervention_name>
    <description>GSK investigational product or placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>Ascending dose based on target exposures or placebo</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>An ascending dose based on target exposure</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>An ascending dose based on target exposures.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascending dose of GSK1292263</intervention_name>
    <description>An ascending dose based on target exposure</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male or female between 18 and 55 years of age

          -  A female subject is eligible to participate if she is of non-childbearing potential

          -  Male subjects must agree to use one of the contraception methods listed in the
             protocol

          -  BMI within the range 20 - 29.9 kg/m2

          -  Capable of giving written informed consent, which includes compliance with protocol

          -  QTcB or QTcF &lt; 450msec.

        Exclusion Criteria:

          -  The subject has a positive pre-study drug/alcohol screen

          -  Positive urinary cotinine levels or history or regular use of tobacco- or
             nicotine-containing products within 6 months prior to screening.

          -  History of regular alcohol consumption within 6 months of the study

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia

          -  Unable or unwilling to abstain from caffeine-or xanthine-containing products for 24
             hours prior to dosing until the final post-dose assessment at each treatment level.

          -  Use of illicit drugs.

          -  Use of alcohol for 24 hours prior to dosing until final post-dose assessment at each
             treatment level.

          -  Consumption of red wine, oranges, grapefruit or grapefruit juice from 7 days prior to
             the first dose of study medication until collection of the final pharmacokinetic and
             pharmacodynamic blood samples

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  A positive test for HIV antibody

          -  Pregnant females as determined by positive urine hCG test at screening or prior to
             dosing

          -  Lactating females

          -  Has a fasting triglyceride level &gt;400mg/dL (4.45mmol/L)

          -  Has anemia defined by hemoglobin concentration &lt;11.0g/dL for males or &lt;10.0g/dL for
             females.

          -  CPK values higher than 2.5 times the upper limit of normal at screening.

          -  Significant ECG abnormalities

          -  abnormal vital signs as defined in the

          -  History of any gastrointestinal or hepatic conditions that could impact absorption of
             the investigational compound.

          -  Family history (first or second degree relatives) with a history of hypertrophic
             cardiomyopathy.

          -  Family history of torsade de pointes or other ventricular arrhythmias.

          -  Family history of unexplained sudden death.

          -  Evidence of early depolarization (e.g., Wolf-Parkinson-White syndrome).

          -  Has clinically significant rhythm abnormalities identified during 24-hour Screening
             Holter assessment.

          -  Subjects who have asthma or a history of asthma

          -  The subject has participated in a clinical trial and has received an investigational
             product within a protocol defined period

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements within 7 days or 14 days if the drug is a potential enzyme inducer or 5
             half-lives prior to the first dose of study medication, unless in the opinion of the
             Investigator and GSK Medical Monitor the medication will not interfere with the study
             procedures or compromise subject safety.

          -  History of sensitivity to any of the study medications or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation

          -  Subjects who are taking low-dose aspirin for cardiovascular prophylaxis (81mg or less)
             are eligible to participate in the study, but the aspirin must be discontinued from
             Screening to the Follow-up visit

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  As a result of the medical interview, physical examination, or screening
             investigations, the investigator considers the subject unfit for the study.

          -  Subject is either an immediate family member of a participating investigator, study
             coordinator, employee of an investigator; or is a member of the staff conducting the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/111596?search=study&amp;study_ids=11596#rs</url>
    <description>Results for study 111596 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerability</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111596</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

